Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Study backs Abbott's fetal lung development test:

This article was originally published in Clinica

Executive Summary

Fears that Abbott Laboratories' fetal lung maturity test, which is performed on amniotic fluid collected from the vagina, may be affected by vaginal discharge, bacteria and mucus have been countered by a 153-patient US study. The TDx/TDxFLx fetal Lung Maturity II test, which has been in use for over five years, provides an accurate and non-invasive method for assessing fetal lung development, according to a team led by Rodney Edwards from the University of Florida College of Medicine. The findings were presented earlier this month at the Society for Maternal-Fetal Medicine meeting in Miami.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT073221

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel